Strategies targeting brown adipose tissue growth and UCP1 activation, such as pharmacological triggering of β3-adrenergic receptors in adipocytes, offer therapeutic approaches to combat diabetes, obesity, and related diseases, even in the absence of natural stimuli [9,10]. The gene discussed is UCP1; the disease is obesity due to melanocortin 4 receptor deficiency.